scispace - formally typeset
Search or ask a question
Posted ContentDOI

A novel phylogenetic analysis combined with a machine learning approach predicts human mitochondrial variant pathogenicity

11 Jan 2020-bioRxiv (Cold Spring Harbor Laboratory)-
TL;DR: A novel and empirical approach for assessing site-specific conservation and variant acceptability that depends upon phylogenetic analysis and ancestral prediction and minimizes current alignment limitations is described and a substantial portion of encountered mtDNA alleles not yet characterized as harmful are, in fact, likely to be deleterious.
Abstract: Linking mitochondrial DNA (mtDNA) mutations to patient outcomes has been a serious challenge. The multicopy nature and potential heteroplasmy of the mitochondrial genome, differential distribution of mutant mtDNAs among various tissues, genetic interactions among alleles, and environmental effects can hamper clinicians as they try to inform patients regarding the etiology of their metabolic disease. Multiple sequence alignments using samples ranging across multiple organisms and taxa are often deployed to assess the overall conservation of any site within a mtDNA-encoded macromolecule and to determine the acceptability of any given variant at a particular position. However, the utility of multiple sequence alignments in pathogenicity prediction can be restricted by factors including sample set bias, alignment errors, and sequencing errors. Here, we describe a novel and empirical approach for assessing site-specific conservation and variant acceptability that depends upon phylogenetic analysis and ancestral prediction and minimizes current alignment limitations. Next, we use machine learning to predict the pathogenicity of thousands of so-far-uncharacterized human alleles catalogued in the clinic. Our work demonstrates that a substantial portion of encountered mtDNA alleles not yet characterized as harmful are, in fact, likely to be deleterious. Beyond general applications of our methodology that lie outside of mitochondrial studies, our findings are likely to be of direct relevance to those at risk of mitochondria-associated illness.

Summary (2 min read)

INTRODUCTION

  • Because of the critical roles that mitochondria play in metabolism and bioenergetics, mutation of mitochondria-localized proteins and ribonucleic acids can adversely affect human health (Alston et al, 2017; Suomalainen & Battersby, 2018; Khan et al, 2020; Russell et al, 2020).
  • Simple tabulation of mtDNA variants found among healthy or sick individuals (Whiffin et al, 2017) may be of limited utility in predicting how harmful a variant may be.
  • First, while knowledge of amino acid physico-chemical properties is widely considered to be informative regarding whether an amino acid substitution may or may not have a damaging effect on protein function (Dayhoff 3 et al, 1978), the site-specific acceptability of a given substitution is ultimately decided within the context of its local protein environment (Zuckerkandl & Pauling, 1965).

RESULTS

  • Mapping apparent substitutions to a phylogenetic tree allows calculation of relative positional conservation in mtDNA-encoded proteins and RNAs Using the sequences of extant species and the predicted ancestral node values, the authors subsequently analyzed each edge of the tree for the presence or absence of substitutions at each aligned human position.
  • When calculated for protein and RNA sites encoded by mammalian mtDNA, it is clear that the TSS (and the ISS, not shown) provides an excellent readout of relative conservation at, and consequent functional importance of, each alignment position.
  • Substitution scores and inferred direct substitutions can be linked to human mtDNA variant pathogenicity Since summation of detected substitutions across a phylogenetic tree provides a robust measure of relative conservation at different macromolecular positions, the authors were confident that a phylogenetic analysis that includes TSSs would also provide information about the pathogenicity of human mtDNA variants.
  • Even so, the distribution of variant frequencies among full-length sequences in GenBank was strikingly different for those mutations for which an IIDS could be identified in their mammalian trees of proteins , and even tRNAs , when compared to those for which an IIDS could not be identified.

A support vector machine predicts harmful mtDNA variants

  • Given the clear presence of deleterious substitutions among so far uncharacterized variants, the authors sought a high-throughput method that could, with confidence, identify these potentially deleterious substitutions.
  • MitoCAP also scored best against their training set when considering most auxiliary measures of prediction proficiency .
  • To further investigate this possibility, the authors first plotted the level of agreement between MitoCAP other methods when assessing all classified variants, and they noted a pronounced lack of overlap between their MitoCAP predictions and the predictions of other methods .
  • When heteroplasmy data for unannotated variants in HelixMTdb are analyzed for other prediction methods , as performed above for MitoCAP, MitoCAP best separated variants into classes with different heteroplasmy propensities and achieved the highest Kolmogorov-Smirnov D score .
  • Taken together, their analyses indicate that MitoCAP appears to be the most proficient among the compared methods in predicting pathogenicity of variants in mtDNA-encoded proteins, while alternative methods may outperform MitoCAP during classification of tRNA variants.

DISCUSSION

  • The authors describe here a methodology that allows improved quantification of the relative conservation of sites within and between genes, RNAs, and proteins.
  • Even nearly identical sequences can be utilized by their approach, allowing for an everincreasing input dataset that can be deployed toward calculation of site-specific conservation.
  • The authors note that focusing upon IIDSs, rather than the simple presence or absence of a character at a site, can indirectly integrate information about potential epistatic interactions that permit or block a substitution from being successfully established within a lineage.
  • The MitoCAP predictions that the authors provide allow for improved comprehension of which mtDNA variants identified within a patient may be linked to mitochondrial disease.
  • Concordantly, their data suggest a strong propensity for heteroplasmy in the set of substitutions that the authors predict to be pathogenic, but are not yet clinically annotated as disease-associated.

METHODOLOGY

  • Mitochondrial DNA sequence acquisition and conservation analysis Mammalian mtDNA sequences were retrieved from the National Center for Biotechnology Information database of organelle genomes (https://www.ncbi.nlm.nih.gov/genome/browse#!/organelles/ on September 26, 2019).
  • The PAGAN output was then analyzed using “binary-table-by-edges-v2.2” and "addconvention-to-binarytable-v1.1.py" (https://github.com/corydunnlab/hummingbird).
  • For proteins, the negative training sets consisted of 50 mtDNA substitutions (encoding 51 protein variants) from the reference sequence.
  • Predictions for the ROC curve were collected using ‘mining’ function of the rminer package (Cortez, 2015), with the optimized parameters during 10 runs of 5-fold cross-validation [model="ksvm", task = "prob", method = c("kfold", 5), Runs = 10].
  • Comparison of selected, alternative prediction methods with MitoCAP Pathogenicity predictions for their training and test set variants were compared to predictions made by PolyPhen-2 (Adzhubei et al, 2013), PROVEAN (Choi et al, 2012), Panther-PSEP (Tang & Thomas, 2016b), Mitoclass (Martín-Navarro et al, 2017) and MitImpact (Castellana et al, 2015).

AUTHOR CONTRIBUTIONS

  • B.A.A. developed software, analyzed data, and edited the manuscript.
  • P.O.C. and V.O.P. analyzed data and edited the manuscript.
  • C.D.D. conceived of the classification approach, supervised the project, analyzed data, prepared figures, and wrote the manuscript.

Did you find this useful? Give us your feedback

Content maybe subject to copyright    Report

A novel phylogenetic analysis and machine learning
predict pathogenicity of human mtDNA variants
Bala Anı Akpınar
1 †
, Paul O. Carlson
1
, Ville O. Paavilainen
1
, and Cory D. Dunn
1 †
1
Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki,
Helsinki, 00014, Finland
Corresponding authors
Correspondence:
Bala Anı Akpınar, Ph.D.
P.O. Box 56
University of Helsinki
00014 Finland
Email: ani.akpinar@helsinki.fi
Phone: +358 50 311 9307
or
Cory Dunn, Ph.D.
P.O. Box 56
University of Helsinki
00014 Finland
Email: cory.dunn@helsinki.fi
Phone: +358 50 311 9307
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprintthis version posted October 10, 2020. ; https://doi.org/10.1101/2020.01.10.902239doi: bioRxiv preprint

ABSTRACT
Linking mitochondrial DNA (mtDNA) variation to clinical outcomes remains a formidable
challenge. Diagnosis of mitochondrial disease is hampered by the multicopy nature and
potential heteroplasmy of the mitochondrial genome, differential distribution of mutant
mtDNAs among various tissues, genetic interactions among alleles, and environmental
effects. Here, we describe a new approach to the assessment of which mtDNA variants may
be pathogenic. Our method takes advantage of site-specific conservation and variant
acceptability metrics that minimize previous classification limitations. Using our novel
features, we deploy machine learning to predict the pathogenicity of thousands of human
mtDNA variants. Our work demonstrates that a substantial fraction of mtDNA changes not
yet characterized as harmful are, in fact, likely to be deleterious. Our findings will be of direct
relevance to those at risk of mitochondria-associated metabolic disease.
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprintthis version posted October 10, 2020. ; https://doi.org/10.1101/2020.01.10.902239doi: bioRxiv preprint

2
INTRODUCTION
Because of the critical roles that mitochondria play in metabolism and bioenergetics,
mutation of mitochondria-localized proteins and ribonucleic acids can adversely affect
human health (Alston et al, 2017; Suomalainen & Battersby, 2018; Khan et al, 2020; Russell
et al, 2020). Indeed, at least one in 5000 people (Gorman et al, 2015) is estimated to be
overtly affected by mitochondrial disease. While a very limited number of mitochondrial DNA
(mtDNA) lesions can be directly linked to human illness, the clinical outcome for many other
mtDNA changes remains ambiguous (Vento & Pappa, 2013). Heteroplasmy among the
hundreds of mitochondrial DNA (mtDNA) molecules found within a cell (Stewart & Chinnery,
2015; Hahn & Zuryn, 2019; Wei & Chinnery, 2020), differential distribution of disease-causing
mtDNA among tissues (Boulet et al, 1992), and modifier alleles within the mitochondrial
genome (Wei et al, 2017; Elliott et al, 2008) magnify the difficulty of interpreting different
mtDNA alterations. Mito-nuclear interactions and environmental effects may also determine
the outcome of mitochondrial DNA mutations (Wolff et al, 2014; Hill et al, 2019; Matilainen et
al, 2017; Turnbull et al, 2018). Beyond the obvious importance of resolving the genetic
etiology of symptoms presented in a clinical setting, the rapidly increasing prominence of
direct-to-consumer genetic testing (Phillips et al, 2018) calls for an improved understanding
of which mtDNA polymorphisms might affect human health (Blell & Hunter, 2019).
Simple tabulation of mtDNA variants found among healthy or sick individuals (Whiffin
et al, 2017) may be of limited utility in predicting how harmful a variant may be. Differing,
strand-specific mutational propensities for mtDNA nucleotides at different locations within
the molecule (Tanaka & Ozawa, 1994; Faith & Pollock, 2003; Reyes et al, 1998) should be
taken into account when assessing population-wide data, yet allele frequencies are rarely, if
ever, normalized in this way. Population sampling biases and recent population bottleneck
effects can lead to misinterpretation of variant frequencies (Zuk et al, 2014; Chheda et al,
2017; Keinan & Clark, 2012; Landry et al, 2018; Pirastu et al, 2020). Mildly deleterious
variants arising in a population are slow to be removed by selection (Nachman, 1998;
Nachman et al, 1996), leading to a false prediction of variant benignancy. Finally, a lack of
selection against variants that might act in a deleterious manner at the post-reproductive
stage of life also makes likely the possibility that some mtDNA changes will contribute to
age-related phenotypes while avoiding overt association with mitochondrial disease
(Maklakov et al, 2015; Medawar, 1952; Cui et al, 2019; Williams, 1957; Wallace, 1994).
Examining evolutionary conservation by use of multiple sequence alignments offers
important assistance when predicting a variant’s potential pathogenicity (Raychaudhuri,
2011; Tang & Thomas, 2016a). However, caveats are also associated with predicting
mutation outcome by the use of these alignments. First, while knowledge of amino acid
physico-chemical properties is widely considered to be informative regarding whether an
amino acid substitution may or may not have a damaging effect on protein function (Dayhoff
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprintthis version posted October 10, 2020. ; https://doi.org/10.1101/2020.01.10.902239doi: bioRxiv preprint

3
et al, 1978), the site-specific acceptability of a given substitution is ultimately decided within
the context of its local protein environment (Zuckerkandl & Pauling, 1965). Second, sampling
biases and improper clade selection may lead to inaccurate clinical interpretations regarding
the relative acceptability of specific variants (Zuk et al, 2014; Chheda et al, 2017; Keinan &
Clark, 2012; Landry et al, 2018). Third, alignment (Kawrykow et al, 2012; Iantorno et al, 2014)
and sequencing errors (Chen et al, 2017; Smith, 2019) may falsely indicate the acceptability
of a particular mtDNA substitution.
Here, we have deployed a methodology to calculate, by a novel analysis of available
mammalian genomes, the relative conservation of human mtDNA-encoded positions.
Moreover, we infer ancestral direct substitutions within mammals and test whether they
match substitutions from the human reference sequence, providing further knowledge
regarding the potential pathogenicity of any human mtDNA substitution. By subsequent
application of machine learning, we demonstrate that a surprising number of
uncharacterized mtDNA mutations carried by humans are likely to promote disease. We
provide our predictions, which should be of great utility to clinicians and to those studying
mitochondrial disease.
RESULTS
Mapping apparent substitutions to a phylogenetic tree allows calculation of relative
positional conservation in mtDNA-encoded proteins and RNAs
We previously developed an empirical method for detection and quantification of
mtDNA substitutions mapped to the edges of a phylogenetic tree (Dunn et al, 2020). Here,
we have extended our approach toward prediction of human mitochondrial variant
pathogenicity. First, we retrieved full mammalian mtDNA sequences from the National
Center for Biotechnology Information Reference Sequence (NCBI RefSeq) database and
extracted each RNA or protein-coding gene using the Homo sapiens reference mtDNA as a
guide. Next, we aligned the resulting protein, tRNA, and rRNA sequences, concatenated the
sequences of each species based upon molecule class, and generated phylogenetic trees
using a maximum likelihood approach. Following tree generation, we performed ancestral
prediction to reconstruct the character values of each position at every bifurcating node.
Using the sequences of extant species and the predicted ancestral node values, we
subsequently analyzed each edge of the tree for the presence or absence of substitutions at
each aligned human position. We subsequently sum all substitutions at a given position that
occur along all tree edges to generate a new metric, the total substitution score (TSS, Figure
1A). The TSS should surpass metrics that consider positional character frequencies derived
from multiple sequence alignments as a proxy of conservation, as character frequencies are
highly sensitive to sampling biases among input sequences. Moreover, many site-specific
measurements of variability, such as Shannon entropy, are limited in dynamic range and
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprintthis version posted October 10, 2020. ; https://doi.org/10.1101/2020.01.10.902239doi: bioRxiv preprint

4
benefit minimally from the rapid increase in available genomic information. In contrast, the
dynamic range of the TSS is very wide, and potentially unlimited, continuously benefitting
from the accretion of new sequence information.
Furthermore, by excluding edges from analysis that lead directly to extant sequences,
one can further minimize effects of alignment errors and sequencing errors that may lead to
eventual misinterpretation of variant pathogenicity. Moreover, mutations mapped to internal
edges are more likely to represent fixed changes informative for the purposes of disease
prediction, while polymorphisms that have not yet been subject to selection of sufficient
strength or duration might be expected to complicate predictions of variant pathogenicity
(Nachman et al, 1996; Nachman, 1998). Summation of substitutions only at these internal
edges provides an internal substitution score (ISS, Figure 1B).
When calculated for protein and RNA sites encoded by mammalian mtDNA, it is clear
that the TSS (and the ISS, not shown) provides an excellent readout of relative conservation
at, and consequent functional importance of, each alignment position. When comparing TSS
data from different mtDNA-encoded proteins, our findings are consistent with previous
results, obtained by alternative methodologies, demonstrating that the core, mtDNA-
encoded subunits of Complexes III and IV tend to be the most conserved, while positions
within the mtDNA-encoded polypeptides of Complex I and Complex V tend to be less well
conserved (da Fonseca et al, 2008; Nabholz et al, 2013) (Figure 2A). Examination of the
structures of these complexes indicate that, indeed, the most conserved residues are
preferentially localized near the key catalytic regions of each complex (not shown). Within
each protein, there was, as expected, a spectrum of site conservation values, also illustrated
by plotting a distribution of TSS values across each polypeptide (Figure S1). Nearly all
analyzed protein positions appeared to be under some selective pressure and are not
saturated with mutations, with TSS values existing far from the maximal values that can be
achieved within this phylogenetic analysis of mammals. Selective pressure on most aligned
sites is also observed when examining mtDNA-encoded tRNAs and rRNAs (Figure 2B and
Figure S2).
Beyond summation of substitutions across a phylogenetic tree, the inferred ancestral
and descendent characters at each edge of the phylogenetic tree can also be examined
following generation of the substitution map and can provide important information
regarding what changes to mtDNA-encoded macromolecules might be deleterious or not.
Specifically, if an inferred direct substitution from the human reference character to the
mutant character (or the inverse, assuming the time-reversibility of character substitutions) is
predicted along the edge of a phylogenetic tree, then such a change at a given position
might be expected to be less deleterious than an inferred direct substitution to or from the
human character that was never encountered over the evolutionary history of a clade. In
contrast, the simple presence or absence of a character at an alignment position, without
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprintthis version posted October 10, 2020. ; https://doi.org/10.1101/2020.01.10.902239doi: bioRxiv preprint

References
More filters
Journal ArticleDOI
TL;DR: An analytical framework for the design of rare variant association studies of disease is described, providing guidance with respect to sample size, as well as the roles of selection, disruptive and missense alleles, gene-specific allele frequency thresholds, isolated populations, gene sets, and coding vs. noncoding regions.
Abstract: Genetic studies have revealed thousands of loci predisposing to hundreds of human diseases and traits, revealing important biological pathways and defining novel therapeutic hypotheses. However, the genes discovered to date typically explain less than half of the apparent heritability. Because efforts have largely focused on common genetic variants, one hypothesis is that much of the missing heritability is due to rare genetic variants. Studies of common variants are typically referred to as genomewide association studies, whereas studies of rare variants are often simply called sequencing studies. Because they are actually closely related, we use the terms common variant association study (CVAS) and rare variant association study (RVAS). In this paper, we outline the similarities and differences between RVAS and CVAS and describe a conceptual framework for the design of RVAS. We apply the framework to address key questions about the sample sizes needed to detect association, the relative merits of testing disruptive alleles vs. missense alleles, frequency thresholds for filtering alleles, the value of predictors of the functional impact of missense alleles, the potential utility of isolated populations, the value of gene-set analysis, and the utility of de novo mutations. The optimal design depends critically on the selection coefficient against deleterious alleles and thus varies across genes. The analysis shows that common variant and rare variant studies require similarly large sample collections. In particular, a well-powered RVAS should involve discovery sets with at least 25,000 cases, together with a substantial replication set.

600 citations


"A novel phylogenetic analysis combi..." refers background in this paper

  • ...Second, sampling biases and improper clade selection may deceive the clinician regarding the relative acceptability of a specific allele (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

  • ...…for strand- and nucleotide-specific mtDNA mutational biases (Tanaka and Ozawa 1994; Reyes et al. 1998; Faith and Pollock 2003), and sampling biases are typically a hazard when carrying out population-wide studies (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

  • ...Moreover, population sampling biases and recent population bottleneck effects can lead to misinterpretation of actual allele frequencies when determining 3 pathogenicity (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

Journal ArticleDOI
TL;DR: In this paper, the authors evaluated the minimum prevalence of symptomatic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases, and found that the mtDNA mutation rate was 1 in 5,000 (20 per 100,000), comparable with the previously published prevalence rates.
Abstract: Objective The prevalence of mitochondrial disease has proven difficult to establish, predominantly as a result of clinical and genetic heterogeneity. The phenotypic spectrum of mitochondrial disease has expanded significantly since the original reports that associated classic clinical syndromes with mitochondrial DNA (mtDNA) rearrangements and point mutations. The revolution in genetic technologies has allowed interrogation of the nuclear genome in a manner that has dramatically improved the diagnosis of mitochondrial disorders. We comprehensively assessed the prevalence of all forms of adult mitochondrial disease to include pathogenic mutations in both nuclear and mtDNA. Methods Adults with suspected mitochondrial disease in the North East of England were referred to a single neurology center from 1990 to 2014. For the midyear period of 2011, we evaluated the minimum prevalence of symptomatic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases. Results The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our previously published prevalence rates. In this population, nuclear mutations were responsible for clinically overt adult mitochondrial disease in 2.9 per 100,000 adults. Interpretation Combined, our data confirm that the total prevalence of adult mitochondrial disease, including pathogenic mutations of both the mitochondrial and nuclear genomes (≈1 in 4,300), is among the commonest adult forms of inherited neurological disorders. These figures hold important implications for the evaluation of interventions, provision of evidence-based health policies, and planning of future services. Ann Neurol 2015 Ann Neurol 2015;77:753–759

591 citations

Journal ArticleDOI
TL;DR: The unique features of mitochondrial genetics are outlined before detailing the diseases and their genetic causes, focusing specifically on primary mtDNA genetic defects.

574 citations

Journal ArticleDOI
11 May 2012-Science
TL;DR: The empirical signatures of explosive growth on the site frequency spectrum are characterized and it is found that the discrepancy in rare variant abundance across demographic modeling studies is mostly due to differences in sample size.
Abstract: Human populations have experienced recent explosive growth, expanding by at least three orders of magnitude over the past 400 generations. This departure from equilibrium skews patterns of genetic variation and distorts basic principles of population genetics. We characterized the empirical signatures of explosive growth on the site frequency spectrum and found that the discrepancy in rare variant abundance across demographic modeling studies is mostly due to differences in sample size. Rapid recent growth increases the load of rare variants and is likely to play a role in the individual genetic burden of complex disease risk. Hence, the extreme recent human population growth needs to be taken into consideration in studying the genetics of complex diseases and traits.

566 citations


"A novel phylogenetic analysis combi..." refers background in this paper

  • ...Second, sampling biases and improper clade selection may deceive the clinician regarding the relative acceptability of a specific allele (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

  • ...…for strand- and nucleotide-specific mtDNA mutational biases (Tanaka and Ozawa 1994; Reyes et al. 1998; Faith and Pollock 2003), and sampling biases are typically a hazard when carrying out population-wide studies (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

  • ...Moreover, population sampling biases and recent population bottleneck effects can lead to misinterpretation of actual allele frequencies when determining 3 pathogenicity (Keinan and Clark 2012; Zuk et al. 2014; Chheda et al. 2017; Landry et al. 2018)....

    [...]

Journal ArticleDOI
TL;DR: At least one in 200 healthy humans harbors a pathogenic mtDNA mutation that potentially causes disease in the offspring of female carriers, and the exclusive detection of m.14484T→C on haplogroup J implicates the background mtDNA haplotype in mutagenesis.
Abstract: Mitochondrial DNA (mtDNA) mutations are a major cause of genetic disease, but their prevalence in the general population is not known. We determined the frequency of ten mitochondrial point mutations in 3168 neonatal-cord-blood samples from sequential live births, analyzing matched maternal-blood samples to estimate the de novo mutation rate. mtDNA mutations were detected in 15 offspring (0.54%, 95% CI = 0.30-0.89%). Of these live births, 0.00107% (95% CI = 0.00087-0.0127) harbored a mutation not detected in the mother's blood, providing an estimate of the de novo mutation rate. The most common mutation was m.3243A-->G. m.14484T-->C was only found on sub-branches of mtDNA haplogroup J. In conclusion, at least one in 200 healthy humans harbors a pathogenic mtDNA mutation that potentially causes disease in the offspring of female carriers. The exclusive detection of m.14484T-->C on haplogroup J implicates the background mtDNA haplotype in mutagenesis. These findings emphasize the importance of developing new approaches to prevent transmission.

532 citations

Frequently Asked Questions (1)
Q1. What are the contributions in "A novel phylogenetic analysis and machine learning predict pathogenicity of human mtdna variants" ?

Here, the authors describe a new approach to the assessment of which mtDNA variants may be pathogenic. ( which was not certified by peer review ) is the author/funder.